How lipoproteins shape your metabolic health
July 11, 2024 / Lipoproteins / Cardiovascular Disease / Dyslipidemia Management
Lipoproteins, including HDL, LDL, and VLDL, transport lipids in the blood, influencing metabolic health. LDL contributes to atherosclerosis and cardiovascular disease (CVD). Dyslipidemia, common in obesity and diabetes, increases CVD risk, with emerging therapies targeting gene modification and lipid regulation.
Reducing cancer risk through better metabolic health
July 15, 2024 / Metabolic Health / Cancer Prevention / Insulin Resistance / Obesity
Better metabolic health, through diet, exercise, and insulin regulation, reduces cancer risk. Metabolic risks like obesity, type 2 diabetes, and physical inactivity are linked to cancers such as endometrial, pancreatic, colorectal, and breast. Effective prevention strategies include lifestyle changes and medications.
Impact of AI on metabolic disorder clinical trials
July 11, 2024 / AI / Clinical Trials / Type 2 Diabetes
AI is transforming metabolic disorder clinical trials by enhancing data-driven research in type 2 diabetes and obesity. Recent trials show AI’s potential to accelerate drug development, improve efficacy, and reduce side effects, highlighting promising advancements in this field.
Adipose glutaminolysis resurfaces in metabolic disease
July 15, 2024 / Glutamine Metabolism / White Adipose Tissue / Metaboli Disease Treatment
Glutamine metabolism in white adipose tissue (WAT) has a newly discovered role in metabolic disease, offering potential therapeutic targets for treatment.
The effect of supplementation with cornelian cherry on different cardiometabolic outcomes
July 7, 2024 / Cornelian Cherry Benefits / Cardiometabolic Health / Glucose Control / HDL Cholesterol / Weight Loss
Cornelian cherry supplementation improves cardiometabolic health by reducing body weight, BMI, fasting blood glucose, and HbA1c levels, and increasing HDL cholesterol. However, further studies are needed to confirm its long-term efficacy and optimal dosing.
Reduced adipocyte glutaminase activity promotes energy expenditure and metabolic health
July 15, 2024 / Glutaminase Activity / Metabolic Health / Insulin Resistance Therapy
Reduced glutaminase activity in white adipocytes enhances energy expenditure and metabolic health by increasing aerobic glycolysis and mitochondrial function, improving glucose tolerance, and activating thermogenic gene programs, highlighting a novel therapeutic target for obesity-associated insulin resistance.
Aging aggravates liver fibrosis in Down Syndrome, new study finds
July 10, 2024 / Down Syndrome / Liver Fibrosis / Oxidative Stress / Lipid Metabolism
Aging increases oxidative stress and liver fibrosis in Down Syndrome, with DS mice showing reduced antioxidant defenses, altered lipid metabolism, and increased fibrosis. This highlights potential therapeutic strategies targeting oxidative stress and lipid metabolism for DS-related liver complications.
FXR activation remodels hepatic and intestinal transcriptional landscapes in metabolic dysfunction-associated steatohepatitis
July 11, 2024 / FXR Activation / Metabolic Dysfunction / MASH Therapy / Liver Fibrosis
FXR activation improves metabolic dysfunction-associated steatohepatitis (MASH) by reversing dysregulated metabolic and inflammatory networks, reducing fibrosis, and immune infiltration in the liver and intestines. This highlights FXR agonists’ potential for targeted MASH therapy.
Repurposing pemafibrate to treat liver disease associated with metabolic disorders
July 10, 2024 / Pemafibrate / Metabolic Liver Disease / MASLD Treatment
A University of Barcelona study suggests repurposing pemafibrate to treat metabolic dysfunction-associated steatotic liver disease (MASLD). Originally for dyslipidemia, pemafibrate shows promise in preventing hepatic steatosis and enhancing fatty acid metabolism in preclinical models.
Testosterone tied to incidence, progression of metabolic syndrome
July 11, 2024 / Testosterone / Metabolic Syndrome / Hormone Treatment
Testosterone increases the risk and progression of metabolic syndrome, especially in transmasculine individuals. Estradiol reduces this risk in both cisgender and transgender individuals, highlighting the need for tailored management of metabolic syndrome in these populations.
Sleep Apnea Raises Chances of Heart Disease, Particularly in Young Adults
July 11, 2024 / Sleep Apnea / Heart Disease / Hypertension Risk / Sleep Disorder
Sleep apnea significantly increases heart disease risk, particularly in young adults. Those aged 20-40 with sleep apnea have higher risks of hypertension, diabetes, and metabolic syndrome, emphasizing the importance of early screening and intervention to mitigate these risks.
PCOS and Metabolic Syndrome Linked Regardless of Inflammation, Menopause Status
July 9, 2024 / PCOS / Metabolic Syndrome / Menopausal Status / Cardiometabolic Risk Factors
PCOS is linked to a higher risk of metabolic syndrome in Hispanic/Latino individuals, independent of inflammation and menopausal status. The study highlights a significant association between PCOS and metabolic health risks, emphasizing the need for targeted interventions.
Amylyx Aims to Help Patients With a Novel GLP-1 Drug, But Not the Way You Think
July 10, 2024 / Avexitide / GLP-1 Receptor Blocker / Metabolic Disease
Amylyx Pharmaceuticals acquired avexitide, a GLP-1 receptor blocker, to treat post-bariatric hypoglycemia (PBH). This drug stabilizes blood glucose levels in PBH patients, preventing severe hypoglycemia, without causing weight gain. Phase 3 trials start in 2025.
Bariatric metabolic surgery is associated with a lower risk for heart failure versus GLP-1RAs
July 15, 2024 / Bariatric Metabolic Surgery / Heart Failure Risk / Obesity / Diabetes / GLP-1 / Weight Loss
Bariatric metabolic surgery reduces the risk of congestive heart failure more effectively than first-generation GLP-1 receptor agonists in adults with obesity and diabetes, independent of weight loss differences between the treatments.
Sensor involved in regulating metabolic health identified
July 15, 2024 / PAQR4 Receptor / Metabolic Disorders / Insulin Resistance
Researchers identified PAQR4, a protein receptor in fat cells, as a sensor for ceramides, lipids linked to metabolic disorders and cancers. Blocking PAQR4 improves metabolic health, suggesting potential for new drugs to reduce ceramide levels.
How Baking Soda Affects People with Type 2 Diabetes
July 10, 2024 / Sodium Bicarbonate / Type 2 Diabetes / Insulin Resistance
Research indicates that sodium bicarbonate (baking soda) affects insulin resistance and inflammation in type 2 diabetes. While it reduces inflammation and increases anti-inflammatory cell synthesis in diabetic rats, it impairs insulin response. Human clinical trials are needed for confirmation.
Delaying diabetes with diet and exercise for 4 years results in better long-term health
July 9, 2024 / Diabetes Prevention / Prediabetes Management / Cardiovascular Risk
Delaying the onset of diabetes by four years through diet and exercise significantly reduces long-term risks of death and diabetes-related complications in prediabetic individuals. This finding underscores the importance of early lifestyle interventions in diabetes prevention.
First Patient Enrolled in a Phase 2 Study in Patients with Type 2 Diabetes with Olatec’s NLRP3 Inhibitor, Dapansutrile
July 11, 2024 / Type 2 Diabetes / Cardiometabolic Risks / Inflammation Redution
Olatec’s Phase 2 DAPAN-DIA trial in Basel, Switzerland, enrolls the first type 2 diabetes patient to test dapansutrile, an NLRP3 inhibitor. The study aims to evaluate the drug’s efficacy and safety in reducing inflammation and cardiometabolic risks, beyond glycemic control.
Study links improved dietary fat quality to reduced cardiovascular and diabetes risk
July 15, 2024 / Dietary Fat Quality / Cardiovasuclar Disease / Type 2 Diabetes
Improved dietary fat quality, specifically increasing unsaturated fats and reducing saturated fats, is linked to reduced risks of cardiovascular diseases and type 2 diabetes. A multilipid score (rMLS) developed from lipidomics data effectively captures these health benefits.
SH2B1 gene defends against obesity via the paraventricular hypothalamus
July 15, 2024 / SH2B1 Gene / Obesity Regulation / Hypothalamus / Metabolic Diseases
The SH2B1 gene regulates appetite via the paraventricular hypothalamus (PVH). Mutations in SH2B1 are linked to obesity, type 2 diabetes, and liver disease. Enhancing SH2B1 activity could offer promising obesity treatments by modulating appetite without significant side effects.